Drugs.com - Monthly Update July 2025
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Drugs.com - Monthly Update July 2025
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
This month we explore groundbreaking FDA approvals including Ekterly for hereditary angioedema, Anzupgo for chronic hand eczema, and the new dosing regimen of Kisunla for Alzheimer’s. We’ll discuss the mechanisms, patient impacts, and data that drive these advancements.
- Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and older, providing symptom relief in just 1.6 hours compared to 6.7 hours with placebo.
- Anzupgo (delgocitinib), the first steroid-free topical treatment approved in the U.S. for moderate to severe chronic hand eczema in adults, working as a pan-Janus kinase inhibitor with twice-daily application to affected areas.
- Kisunla (donanemab-azbt), now available with an updated once-monthly dosing regimen for early symptomatic Alzheimer's disease, showing a 41% reduction in ARIA-E (amyloid-related imaging abnormalities with edema) at 24 weeks while targeting and removing beta-amyloid plaques in the brain.
Chapters
- (00:00) - Intro
- (00:24) - Overview
- (00:47) - Angioedema
- (01:10) - Ekterly
- (01:51) - Anzupgo
- (02:54) - Kisunla
- (03:45) - Outro
Follow Drugs.com:
- X, Facebook, Youtube
- Signup to our newsletters
- Download the app
Pas encore de commentaire